PL1904490T3 - Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl]phenyl) pyridine-3- sulphonamide - Google Patents

Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl]phenyl) pyridine-3- sulphonamide

Info

Publication number
PL1904490T3
PL1904490T3 PL06755779T PL06755779T PL1904490T3 PL 1904490 T3 PL1904490 T3 PL 1904490T3 PL 06755779 T PL06755779 T PL 06755779T PL 06755779 T PL06755779 T PL 06755779T PL 1904490 T3 PL1904490 T3 PL 1904490T3
Authority
PL
Poland
Prior art keywords
methylpyrazin
sulphonamide
pyridine
methoxy
phenyl
Prior art date
Application number
PL06755779T
Other languages
Polish (pl)
Inventor
Catherine Good
Phillip John Hogan
Frank Montgomery
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1904490T3 publication Critical patent/PL1904490T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide ethanolamine salt and its uses are described.
PL06755779T 2005-07-19 2006-07-17 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl]phenyl) pyridine-3- sulphonamide PL1904490T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0514743.4A GB0514743D0 (en) 2005-07-19 2005-07-19 Salt
EP06755779A EP1904490B1 (en) 2005-07-19 2006-07-17 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl]phenyl) pyridine-3- sulphonamide
PCT/GB2006/002654 WO2007010235A1 (en) 2005-07-19 2006-07-17 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide

Publications (1)

Publication Number Publication Date
PL1904490T3 true PL1904490T3 (en) 2011-02-28

Family

ID=34897419

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06755779T PL1904490T3 (en) 2005-07-19 2006-07-17 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl]phenyl) pyridine-3- sulphonamide

Country Status (23)

Country Link
US (2) US20080221124A1 (en)
EP (1) EP1904490B1 (en)
JP (1) JP5085544B2 (en)
KR (1) KR20080031042A (en)
CN (1) CN101223165B (en)
AT (1) ATE482952T1 (en)
AU (1) AU2006271420B2 (en)
CA (1) CA2615596A1 (en)
CY (1) CY1110942T1 (en)
DE (1) DE602006017220D1 (en)
DK (1) DK1904490T3 (en)
ES (1) ES2351442T3 (en)
GB (1) GB0514743D0 (en)
HK (1) HK1118276A1 (en)
HR (1) HRP20100621T1 (en)
IL (1) IL188389A0 (en)
MX (1) MX2008000889A (en)
NO (1) NO20080053L (en)
PL (1) PL1904490T3 (en)
PT (1) PT1904490E (en)
SI (1) SI1904490T1 (en)
WO (1) WO2007010235A1 (en)
ZA (1) ZA200800328B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0914287D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Compositions
CN102491973A (en) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Synthetic method for ZD (Zero Defects)-4054

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
UA58494C2 (en) * 1995-06-07 2003-08-15 Зенека Лімітед N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical composition, process for preparing thereof and method for endothelin influence counteraction
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (en) * 2001-11-09 2003-05-22 Merck Patent Gmbh Use of endothelin receptor antagonists for the treatment of tumor diseases
EP1458715B1 (en) * 2001-12-18 2005-12-07 AstraZeneca AB Novel compounds
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
DK1904490T3 (en) 2010-12-13
ES2351442T3 (en) 2011-02-04
GB0514743D0 (en) 2005-08-24
ZA200800328B (en) 2008-12-31
WO2007010235A1 (en) 2007-01-25
NO20080053L (en) 2008-04-16
HK1118276A1 (en) 2009-02-06
AU2006271420B2 (en) 2010-09-23
MX2008000889A (en) 2008-03-18
AU2006271420A1 (en) 2007-01-25
EP1904490A1 (en) 2008-04-02
CY1110942T1 (en) 2015-06-10
US20120101109A1 (en) 2012-04-26
JP5085544B2 (en) 2012-11-28
SI1904490T1 (en) 2010-12-31
HRP20100621T1 (en) 2010-12-31
EP1904490B1 (en) 2010-09-29
DE602006017220D1 (en) 2010-11-11
CA2615596A1 (en) 2007-01-25
WO2007010235A8 (en) 2008-03-13
CN101223165B (en) 2011-10-19
JP2009501774A (en) 2009-01-22
PT1904490E (en) 2010-11-18
IL188389A0 (en) 2008-04-13
US20080221124A1 (en) 2008-09-11
CN101223165A (en) 2008-07-16
KR20080031042A (en) 2008-04-07
ATE482952T1 (en) 2010-10-15

Similar Documents

Publication Publication Date Title
EA200701396A1 (en) TRIAZOLOPHTHALASINS AS PDE-2 INHIBITORS
EA200800201A1 (en) CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHILIMIDAZOL-1-IL) -5-TRIFTOROMETHYLPHENYL] -3- (4-Pyridine-3-Ilpyrimidine-2-Ylamino) Benzamide
MX2009006579A (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carbox amide as well as prodrugs and salts thereof for the treatment of cancer.
NO20072058L (en) Inhibitors of the interaction between MDM2 and P53
RS50660B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
CY1111752T1 (en) PYRROLOPYRAZOLES, DYNAMIC MOVEMENT SUSPENSIONS
EA200900613A1 (en) SPIROKETONE ACETYL-COA-CARBOXYLAS INHIBITORS
CY1110026T1 (en) Piperazine benzisoxazole compounds and methods of use thereof
RS52169B (en) Stable laquinimod preparations
EA200801291A1 (en) CARBONYLAMINOPYRROPYRAZOLES AS AN EFFICIENT KINAZ INHIBITORS
HRP20090229T1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
EA201000888A1 (en) 4-PHENYPYRANE-3,5-DIONES, 4-PHENYLTYOPYRANE-3,5-DIONS AND 2-PHENYLCYCLOGEXAN-1,3,5-TRIONS AS HERBICIDES
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
RS50629B (en) Amide prodrug of gemcitabine, compositions and use thereof
EA200601568A1 (en) NEW HYDROXY-8-HETEROARRYFENANTHRIDINES AND THEIR APPLICATION AS PDE4 INHIBITORS
MX2010003989A (en) Composition 064.
EA200801413A1 (en) HETEROCYCLIC CETR INHIBITORS
IS7766A (en) N- (3-methoxy-5-methylpyrazin-2-yl) -2- (4- [1,3,4-oxadiazol-2-yl] phenyl) pyridine-3-sulfonamide as an anticancer drug
EA200801351A1 (en) FUNGICIDAL MIXTURES THAT CONTAIN BOSCALIDE AND PIRIMETHANYL
NO20062629L (en) Oxazole derivatives of tetracklines
IS2473B (en) Composition containing N- (3-methoxy-5-methylpyrazin-2-yl) -2- (4- (1,3,4-oxadiazol-2-yl) phenyl) pyridine-3-sulfonamide (ZD4054), or pharmaceutically its recognized salt, and EGFR TKI, or its pharmaceutically acceptable salt
NO20080133L (en) Azolopyridin-2-one derivatives such as lipase and phospholipase inhibitors
NO20080035L (en) Benzooksazol-2-one derivatives such as lipase and phospholipase inhibitors
CY1110942T1 (en) N- (3-Methoxy-ethoxy-5-methylpyrazin-2-yl) -2- (4- [1,3,4-oxadiazol-2-yl] phenyl) PYRIDINO-3-SULFINE SALT
WO2003047517A3 (en) Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa